Logo Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals (ARWR) stock: analyst price target and their real reliability

Live quote · data updated Oct 14, 2026
Arrowhead Pharmaceuticals · Health Care · ref. ETF XLV · 93 calls · price $58.13
🔔Price alertsCreate an alert →
What the company does: Arrowhead Pharmaceuticals, Inc., founded in 1989 and based in Pasadena, California, is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for complex and challenging-to-treat diseases within the United States.

📈 Arrowhead Pharmaceuticals (ARWR) stock price

$58.13+61.7% over range
Oct 14, 25low $35.96 · high $89.59Oct 13, 26
📏 Click 2 points (left → right) to measure the change · click again to clear.
SellBuy
Buy
82% recommend buying · 11 analysts
📊 JPI status : Arrowhead Pharmaceuticals is currently in 🎯 JPI Fair n°16 · ⚡ JPI Risk + n°18. Also present in past years.

🎯 ARWR price target & analyst consensus — price $58.13

The price target · all analysts combined (11 targets)
Highest target · 1 firm of 11$126+116.8%
Median target · of 11 targets$108+85.8%
Lowest target · 1 firm of 11$46-20.9%
Current price$58.13
Where these 11 targets sit · versus the current price · 1 target per firm, last 6 months
Above the price 1091% $72 ↔ $126
Below 19% $46
⭐ What the most reliable analysts say · those who beat their sector, targets replayed on real prices

⭐ The most reliable of them, either direction: HC Wainwright & Co. — 71% of its targets hit on this sector (248 calls tested). It aims for $120 (+106 %), call made on September 2, 2026, maturing on September 2, 2027 (42 d ago).

The 6 reliable analysts $112+92 %
The 5 other firms $98+69 %
How to read it: the 6 reliable firms are not filtered by optimism — 6 aim above the price, 0 below, hence their $112 median. “The 5 others” are the firms that don't pass our reliability filter on this sector.
The consensus · 11 ratings (last 6 months)
Strong Buy00%
Buy982%
Hold218%
Sell00%
Strong Sell00%
Go deeper on the analysts
All analysts (the consensus)  ·  vs  ·  the best (those who've been right)
💬 A question about Arrowhead Pharmaceuticals? The JPI assistant answers using our backtest data.

📈 Arrowhead Pharmaceuticals fundamentals: valuation, margins & growth › open the full page

P/E —Net margin -47.8 %Revenue growth +171.0 %Not (yet) profitable

Revenue, net income and margin per year

Revenue Net income · hover a bar for details
2022
marg. -72 %
2023
Rev −1%
2024
Rev −99%
2025
Rev +23258%

🔎 Detailed analyses

✅ Historical analyst reliability on ARWR

Hit rate measured on targets already matured (12 months), replayed against real prices. Click a header to sort.

Firm ↕ % right i ↕ Gain vs sector i ↕ Calls i ↕
Baird ↗ 75% +21.3% 4
Cantor Fitzgerald ↗ 62% +73.5% 8
HC Wainwright & Co. ↗ 50% +63.3% 26
B. Riley Securities ↗ 50% +42.0% 10
Piper Sandler ↗ 50% +38.0% 10
B of A Securities ↗ 50% -17.0% 2
Chardan Capital 42% +59.7% 19
RBC Capital ↗ 42% +47.0% 12
Jefferies ↗ 33% +29.9% 3
Goldman Sachs ↗ 25% -28.3% 4

📊 What $1,000 invested in Arrowhead Pharmaceuticals would be worth › open the full page

In short — $1,000 invested in Arrowhead Pharmaceuticals 10 years ago would be worth $13,254 today, i.e. +29%/yr on average. Best year: 2019 (+411%), worst: 2016 (-75%). Price performance, excluding dividends.

If I'd invested $1,000 in Arrowhead Pharmaceuticals

InvestmentWorth todayGain
1 years ago$4,336+334%
3 years ago$2,010+101%
5 years ago$1,062+6%
→ See Arrowhead Pharmaceuticals's full return history + gain calculator

Return by year (Arrowhead Pharmaceuticals)

YearReturn$1,000 invested at year start
2026 (YTD)+23%$1,228 (+23%)
2025+253%$4,336 (+334%)
2024-39%$2,664 (+166%)
→ See Arrowhead Pharmaceuticals's full return history + gain calculator
⚠️ Past performance, not predictive nor advice. Prices in $, excluding dividends. Yahoo Finance data.

📰 Recent news on Arrowhead Pharmaceuticals

Loading news…

📋 All analyst calls on ARWR

Citigroup ↗
Sep 8, 26
▲ Buy · 🎯$108
Price at call : $82.63 — upside +31%
Today : $58.13 — upside +86%
🎯 on ARWR : no call matured yet · 📊 on Health : 57% · +17.6% (128 calls)
in progress (365j)
matures : Sep 8, 27
▲ Buy · 🎯$120
Price at call : $82.74 — upside +45%
Today : $58.13 — upside +106%
🎯 on ARWR : 100% (12 calls matureds) · 📊 on Health : 69% · +25.4% (248 calls)
in progress (365j)
matures : Sep 1, 27
Chardan Capital
Aug 31, 26
▲ Buy · 🎯$115
Price at call : $82.39 — upside +40%
Today : $58.13 — upside +98%
🎯 on ARWR : 42% (19 calls matureds) · 📊 on Health : 60.5% · +52.5% (38 calls)
in progress (365j)
matures : Aug 31, 27
RBC Capital ↗
Aug 31, 26
▲ Outperform · 🎯$100
Price at call : $82.39 — upside +21%
Today : $58.13 — upside +72%
🎯 on ARWR : 100% (2 calls matureds) · 📊 on Health : 48.8% · +6.8% (201 calls)
in progress (365j)
matures : Aug 31, 27
▲ Buy · 🎯$120
Price at call : $87.65 — upside +37%
Today : $58.13 — upside +106%
🎯 on ARWR : 100% (12 calls matureds) · 📊 on Health : 69% · +25.4% (248 calls)
in progress (365j)
matures : Aug 6, 27
▲ Buy · 🎯$123
Price at call : $84.65 — upside +45%
Today : $58.13 — upside +112%
🎯 on ARWR : 50% (10 calls matureds) · 📊 on Health : 52% · +22.0% (25 calls)
in progress (365j)
matures : Jul 30, 27
▲ Buy · 🎯$115
Price at call : $85.53 — upside +34%
Today : $58.13 — upside +98%
🎯 on ARWR : 100% (12 calls matureds) · 📊 on Health : 69% · +25.4% (248 calls)
in progress (365j)
matures : Jul 27, 27
Morgan Stanley ↗
Jul 23, 26
▲ Overweight · 🎯$120
Price at call : $85.6 — upside +40%
Today : $58.13 — upside +106%
🎯 on ARWR : no call matured yet · 📊 on Health : 42% · -0.8% (200 calls)
in progress (365j)
matures : Jul 23, 27
See the other 85 calls, newest to oldest
Piper Sandler ↗
Jul 23, 26
▲ Overweight · 🎯$126
Price at call : $85.6 — upside +47%
Today : $58.13 — upside +117%
🎯 on ARWR : no call matured yet · 📊 on Health : 42.5% · +4.1% (120 calls)
in progress (365j)
matures : Jul 23, 27
Chardan Capital
Jul 22, 26
▲ Buy · 🎯$115
Price at call : $86.78 — upside +33%
Today : $58.13 — upside +98%
🎯 on ARWR : 42% (19 calls matureds) · 📊 on Health : 60.5% · +52.5% (38 calls)
in progress (365j)
matures : Jul 22, 27
JP Morgan ↗
Jul 17, 26
▲ Overweight · 🎯$95
Price at call : $71.65 — upside +33%
Today : $58.13 — upside +63%
🎯 on ARWR : no call matured yet · 📊 on Health : 49% · +7.1% (147 calls)
in progress (365j)
matures : Jul 17, 27
Stifel ↗
Jul 14, 26
▲ Buy · 🎯$98
Price at call : $71.91 — upside +36%
Today : $58.13 — upside +69%
🎯 on ARWR : no call matured yet · 📊 on Health : 48% · +12.3% (100 calls)
in progress (365j)
matures : Jul 14, 27
▲ Buy · 🎯$100
Price at call : $83.99 — upside +19%
Today : $58.13 — upside +72%
🎯 on ARWR : 100% (12 calls matureds) · 📊 on Health : 69% · +25.4% (248 calls)
in progress (365j)
matures : Jul 1, 27
Chardan Capital
Jun 30, 26
▲ Buy · 🎯$90
Price at call : $81.51 — upside +10%
Today : $58.13 — upside +55%
🎯 on ARWR : 42% (19 calls matureds) · 📊 on Health : 60.5% · +52.5% (38 calls)
in progress (365j)
matures : Jun 30, 27
■ Market Perform neutral · not a buy · 🎯$72
Price at call : $81.82 — gap to target -12%
Today : $58.13 — gap to target +24%
🎯 on ARWR : no call matured yet · 📊 on Health : 58.3% · +20.9% (12 calls)
in progress (365j)
matures : Jun 17, 27
Bernstein ↗
May 13, 26
■ Market Perform neutral · not a buy · 🎯$46
Price at call : $79.69 — gap to target -42%
Today : $58.13 — gap to target -21%
🎯 on ARWR : no call matured yet · 📊 on Health : 42.9% · -5.6% (7 calls)
in progress (365j)
matures : May 13, 27
RBC Capital ↗
May 8, 26
▲ Outperform · 🎯$87
Price at call : $77.74 — upside +12%
Today : $58.13 — upside +50%
🎯 on ARWR : 100% (2 calls matureds) · 📊 on Health : 48.8% · +6.8% (201 calls)
in progress (365j)
matures : May 8, 27
JP Morgan ↗
May 1, 26
▲ Overweight · 🎯$88
Price at call : $74.81 — upside +18%
Today : $58.13 — upside +51%
🎯 on ARWR : no call matured yet · 📊 on Health : 49% · +7.1% (147 calls)
in progress (365j)
matures : May 1, 27
Morgan Stanley ↗
Apr 21, 26
▲ Overweight · 🎯$100
Price at call : $71.05 — upside +41%
Today : $58.13 — upside +72%
🎯 on ARWR : no call matured yet · 📊 on Health : 42% · -0.8% (200 calls)
in progress (365j)
matures : Apr 21, 27
▲ Buy · 🎯$100
Price at call : $60.77 — upside +65%
Today : $58.13 — upside +72%
🎯 on ARWR : 100% (12 calls matureds) · 📊 on Health : 69% · +25.4% (248 calls)
in progress (365j)
matures : Mar 25, 27
▲ Buy · 🎯$100
Price at call : $62.92 — upside +59%
Today : $58.13 — upside +72%
🎯 on ARWR : 100% (12 calls matureds) · 📊 on Health : 69% · +25.4% (248 calls)
in progress (365j)
matures : Feb 10, 27
▲ Buy · 🎯$101
Price at call : $69.59 — upside +45%
Today : $58.13 — upside +74%
🎯 on ARWR : 50% (10 calls matureds) · 📊 on Health : 52% · +22.0% (25 calls)
in progress (365j)
matures : Jan 22, 27
▲ Buy · 🎯$100
Price at call : $69.59 — upside +44%
Today : $58.13 — upside +72%
🎯 on ARWR : 100% (12 calls matureds) · 📊 on Health : 69% · +25.4% (248 calls)
in progress (365j)
matures : Jan 21, 27
Piper Sandler ↗
Jan 13, 26
▲ Overweight · 🎯$110
Price at call : $65.91 — upside +67%
Today : $58.13 — upside +89%
🎯 on ARWR : no call matured yet · 📊 on Health : 42.5% · +4.1% (120 calls)
in progress (365j)
matures : Jan 13, 27
Goldman Sachs ↗
Jan 7, 26
■ Neutral neutral · not a buy · 🎯$85
Price at call : $65 — gap to target +31%
Today : $58.13 — gap to target +46%
🎯 on ARWR : no call matured yet · 📊 on Health : 59.5% · +16.1% (111 calls)
in progress (365j)
matures : Jan 7, 27
■ Equal-Weight neutral · not a buy · 🎯$81
Price at call : $65 — gap to target +25%
Today : $58.13 — gap to target +39%
🎯 on ARWR : no call matured yet · 📊 on Health : 42% · -0.8% (200 calls)
in progress (365j)
matures : Jan 7, 27
▲ Buy · 🎯$80
Price at call : $65.69 — upside +22%
Today : $58.13 — upside +38%
🎯 on ARWR : 42% (19 calls matureds) · 📊 on Health : 60.5% · +52.5% (38 calls)
in progress (365j)
matures : Jan 7, 27
Piper Sandler ↗
Dec 17, 25
▲ Overweight · 🎯$100
Price at call : $64.8 — upside +54%
Today : $58.13 — upside +72%
🎯 on ARWR : no call matured yet · 📊 on Health : 42.5% · +4.1% (120 calls)
in progress (365j)
matures : Dec 17, 26
RBC Capital ↗
Dec 11, 25
▲ Outperform · 🎯$80
Price at call : $70.09 — upside +14%
Today : $58.13 — upside +38%
🎯 on ARWR : 100% (2 calls matureds) · 📊 on Health : 48.8% · +6.8% (201 calls)
in progress (365j)
matures : Dec 11, 26
▲ Buy · 🎯$81
Price at call : $68.87 — upside +18%
Today : $58.13 — upside +39%
🎯 on ARWR : no call matured yet · 📊 on Health : 64.2% · +20.2% (109 calls)
in progress (365j)
matures : Dec 9, 26
▲ Buy · 🎯$85
Price at call : $57.95 — upside +47%
Today : $58.13 — upside +46%
🎯 on ARWR : 100% (12 calls matureds) · 📊 on Health : 69% · +25.4% (248 calls)
in progress (365j)
matures : Dec 2, 26
▲ Buy · 🎯$62
Price at call : $57.95 — upside +7%
Today : $58.13 — upside +7%
🎯 on ARWR : no call matured yet · 📊 on Health : 64.2% · +20.2% (109 calls)
in progress (365j)
matures : Dec 1, 26
▲ Buy · 🎯$60
Price at call : $56.25 — upside +7%
Today : $58.13 — upside +3%
🎯 on ARWR : 42% (19 calls matureds) · 📊 on Health : 60.5% · +52.5% (38 calls)
in progress (365j)
matures : Dec 1, 26
Morgan Stanley ↗
Nov 26, 25
■ Equal-Weight neutral · not a buy · 🎯$48
Price at call : $52.7 — gap to target -9%
Today : $58.13 — gap to target -17%
🎯 on ARWR : no call matured yet · 📊 on Health : 42% · -0.8% (200 calls)
in progress (365j)
matures : Nov 26, 26
Goldman Sachs ↗
Nov 20, 25
■ Neutral neutral · not a buy · 🎯$48
Price at call : $38.09 — gap to target +26%
Today : $58.13 — gap to target -17%
🎯 on ARWR : no call matured yet · 📊 on Health : 59.5% · +16.1% (111 calls)
in progress (365j)
matures : Nov 20, 26
RBC Capital ↗
Nov 19, 25
▲ Outperform · 🎯$52
Price at call : $38.09 — upside +37%
Today : $58.13 — upside -11%
🎯 on ARWR : 100% (2 calls matureds) · 📊 on Health : 48.8% · +6.8% (201 calls)
in progress (365j)
matures : Nov 19, 26
Chardan Capital
Nov 19, 25
▲ Buy · 🎯$60
Price at call : $38.97 — upside +54%
Today : $58.13 — upside +3%
🎯 on ARWR : 42% (19 calls matureds) · 📊 on Health : 60.5% · +52.5% (38 calls)
in progress (365j)
matures : Nov 19, 26
Piper Sandler ↗
Nov 19, 25
▲ Overweight · 🎯$70
Price at call : $38.97 — upside +80%
Today : $58.13 — upside +20%
🎯 on ARWR : no call matured yet · 📊 on Health : 42.5% · +4.1% (120 calls)
in progress (365j)
matures : Nov 19, 26
Morgan Stanley ↗
Nov 12, 25
■ Equal-Weight neutral · not a buy · 🎯$45
Price at call : $41.14 — gap to target +9%
Today : $58.13 — gap to target -23%
🎯 on ARWR : no call matured yet · 📊 on Health : 42% · -0.8% (200 calls)
in progress (365j)
matures : Nov 12, 26
▲ Buy · 🎯$80
Price at call : $36.94 — upside +117%
Today : $58.13 — upside +38%
Expected +117% · Actual +64% · Reason (≥ +15%) : ✓ Yes
🎯 on ARWR : 100% (12 calls matureds) · 📊 on Health : 69% · +25.4% (248 calls)
+64.4%
stock +64% · XLV +16%
matured Oct 8, 26
▲ Buy · 🎯$80
Price at call : $27.8 — upside +188%
Today : $58.13 — upside +38%
Expected +188% · Actual +211% · Reason (≥ +15%) : ✓ Yes
🎯 on ARWR : 100% (12 calls matureds) · 📊 on Health : 69% · +25.4% (248 calls)
+211.1%
stock +211% · XLV +27%
matured Sep 2, 26
Chardan Capital
Aug 11, 25
▲ Buy · 🎯$60
Price at call : $17.21 — upside +249%
Today : $58.13 — upside +3%
Expected +249% · Actual +419% · Reason (≥ +15%) : ✓ Yes
🎯 on ARWR : 42% (19 calls matureds) · 📊 on Health : 60.5% · +52.5% (38 calls)
+418.5%
stock +419% · XLV +29%
matured Aug 11, 26
RBC Capital ↗
Aug 8, 25
▲ Outperform · 🎯$38
Price at call : $17.21 — upside +121%
Today : $58.13 — upside -35%
Expected +121% · Actual +413% · Reason (≥ +15%) : ✓ Yes
🎯 on ARWR : 100% (2 calls matureds) · 📊 on Health : 48.8% · +6.8% (201 calls)
+413.3%
stock +413% · XLV +29%
matured Aug 8, 26
▲ Buy · 🎯$80
Price at call : $16.29 — upside +391%
Today : $58.13 — upside +38%
Expected +391% · Actual +374% · Reason (≥ +15%) : ✓ Yes
🎯 on ARWR : 100% (12 calls matureds) · 📊 on Health : 69% · +25.4% (248 calls)
+373.5%
stock +374% · XLV +9%
matured May 20, 26
Citigroup ↗
May 13, 25
■ Neutral neutral · not a buy · 🎯$17
Price at call : $14.91 — gap to target +14%
Today : $58.13 — gap to target -71%
🎯 on ARWR : no call matured yet · 📊 on Health : 57% · +17.6% (128 calls)
in progress (365j)
matures : May 13, 26
Chardan Capital
May 13, 25
▲ Buy · 🎯$60
Price at call : $15.28 — upside +293%
Today : $58.13 — upside +3%
Expected +293% · Actual +410% · Reason (≥ +15%) : ✓ Yes
🎯 on ARWR : 42% (19 calls matureds) · 📊 on Health : 60.5% · +52.5% (38 calls)
+409.7%
stock +410% · XLV +11%
matured May 13, 26
▲ Buy · 🎯$38
Price at call : $20.44 — upside +86%
Today : $58.13 — upside -35%
Expected +86% · Actual +212% · Reason (≥ +15%) : ✓ Yes
🎯 on ARWR : 50% (10 calls matureds) · 📊 on Health : 52% · +22.0% (25 calls)
+211.6%
stock +212% · XLV +9%
matured Feb 14, 26
▲ Buy · 🎯$80
Price at call : $18.57 — upside +331%
Today : $58.13 — upside +38%
Expected +331% · Actual +236% · Reason (≥ +15%) : ✓ Yes
🎯 on ARWR : 100% (12 calls matureds) · 📊 on Health : 69% · +25.4% (248 calls)
+235.9%
stock +236% · XLV +7%
matured Feb 12, 26
RBC Capital ↗
Feb 11, 25
▲ Outperform · 🎯$42
Price at call : $18.57 — upside +126%
Today : $58.13 — upside -28%
Expected +126% · Actual +236% · Reason (≥ +15%) : ✓ Yes
🎯 on ARWR : 100% (2 calls matureds) · 📊 on Health : 48.8% · +6.8% (201 calls)
+235.9%
stock +236% · XLV +7%
matured Feb 11, 26
Chardan Capital
Feb 11, 25
▲ Buy · 🎯$60
Price at call : $18.89 — upside +218%
Today : $58.13 — upside +3%
Expected +218% · Actual +226% · Reason (≥ +15%) : ✓ Yes
🎯 on ARWR : 42% (19 calls matureds) · 📊 on Health : 60.5% · +52.5% (38 calls)
+225.8%
stock +226% · XLV +7%
matured Feb 11, 26
▲ Buy · 🎯$80
Price at call : $21.53 — upside +272%
Today : $58.13 — upside +38%
Expected +272% · Actual +211% · Reason (≥ +15%) : ✓ Yes
🎯 on ARWR : 100% (12 calls matureds) · 📊 on Health : 69% · +25.4% (248 calls)
+211.4%
stock +211% · XLV +9%
matured Jan 23, 26
▲ Buy · 🎯$80
Price at call : $19.71 — upside +306%
Today : $58.13 — upside +38%
Expected +306% · Actual +253% · Reason (≥ +15%) : ✓ Yes
🎯 on ARWR : 100% (12 calls matureds) · 📊 on Health : 69% · +25.4% (248 calls)
+253.1%
stock +253% · XLV +11%
matured Jan 22, 26
▲ Buy · 🎯$80
Price at call : $19.75 — upside +305%
Today : $58.13 — upside +38%
Expected +305% · Actual +249% · Reason (≥ +15%) : ✓ Yes
🎯 on ARWR : 100% (12 calls matureds) · 📊 on Health : 69% · +25.4% (248 calls)
+249.4%
stock +249% · XLV +12%
matured Dec 20, 25
Chardan Capital
Dec 12, 24
▲ Buy · 🎯$60
Price at call : $22.14 — upside +171%
Today : $58.13 — upside +3%
Expected +171% · Actual +217% · Reason (≥ +15%) : ✓ Yes
🎯 on ARWR : 42% (19 calls matureds) · 📊 on Health : 60.5% · +52.5% (38 calls)
+216.6%
stock +217% · XLV +9%
matured Dec 12, 25
▲ Buy · 🎯$80
Price at call : $23.11 — upside +246%
Today : $58.13 — upside +38%
Expected +246% · Actual +180% · Reason (≥ +15%) : ✓ Yes
🎯 on ARWR : 100% (12 calls matureds) · 📊 on Health : 69% · +25.4% (248 calls)
+179.8%
stock +180% · XLV +5%
matured Dec 3, 25
Bernstein ↗
Nov 29, 24
■ Market Perform neutral · not a buy · 🎯$24
Price at call : $26.03 — gap to target -8%
Today : $58.13 — gap to target -59%
🎯 on ARWR : no call matured yet · 📊 on Health : 42.9% · -5.6% (7 calls)
in progress (365j)
matures : Nov 29, 25
Chardan Capital
Nov 27, 24
▲ Buy · 🎯$60
Price at call : $26.15 — upside +129%
Today : $58.13 — upside +3%
Expected +129% · Actual +102% · Reason (≥ +15%) : ✓ Yes
🎯 on ARWR : 42% (19 calls matureds) · 📊 on Health : 60.5% · +52.5% (38 calls)
+101.5%
stock +102% · XLV +7%
matured Nov 27, 25
▲ Buy · 🎯$60
Price at call : $18.28 — upside +228%
Today : $58.13 — upside +3%
Expected +228% · Actual +121% · Reason (≥ +15%) : ✓ Yes
🎯 on ARWR : 100% (12 calls matureds) · 📊 on Health : 69% · +25.4% (248 calls)
+121.3%
stock +121% · XLV +7%
matured Nov 20, 25
▲ Buy · 🎯$60
Price at call : $19.36 — upside +210%
Today : $58.13 — upside +3%
Expected +210% · Actual +87% · Reason (≥ +15%) : ✓ Yes
🎯 on ARWR : 100% (12 calls matureds) · 📊 on Health : 69% · +25.4% (248 calls)
+87.2%
stock +87% · XLV -8%
matured Oct 11, 25
▲ Overweight
Actual +35% · Reason (≥ +15%) : ✓ Yes
🎯 on ARWR : 63% (8 calls matureds) · 📊 on Health : 56.4% · +17.2% (117 calls)
+34.6%
stock +35% · XLV -12%
matured Sep 9, 25
▲ Buy · 🎯$60
Price at call : $23.25 — upside +158%
Today : $58.13 — upside +3%
Expected +158% · Actual +25% · Reason (≥ +15%) : ✓ Yes
🎯 on ARWR : 100% (12 calls matureds) · 📊 on Health : 69% · +25.4% (248 calls)
+25.1%
stock +25% · XLV -11%
matured Sep 5, 25
▲ Buy · 🎯$60
Price at call : $23.98 — upside +150%
Today : $58.13 — upside +3%
Expected +150% · Actual +17% · Reason (≥ +15%) : ✓ Yes
🎯 on ARWR : 100% (12 calls matureds) · 📊 on Health : 69% · +25.4% (248 calls)
+16.8%
stock +17% · XLV -12%
matured Sep 3, 25
▲ Buy · 🎯$55
Price at call : $22.85 — upside +141%
Today : $58.13 — upside -5%
Expected +141% · Actual -13% · Reason (≥ +15%) : ✗ No
🎯 on ARWR : 50% (10 calls matureds) · 📊 on Health : 52% · +22.0% (25 calls)
-12.5%
stock -13% · XLV -12%
matured Aug 12, 25
Chardan Capital
Jul 17, 24
▲ Buy · 🎯$60
Price at call : $27.64 — upside +117%
Today : $58.13 — upside +3%
Expected +117% · Actual -39% · Reason (≥ +15%) : ✗ No
🎯 on ARWR : 42% (19 calls matureds) · 📊 on Health : 60.5% · +52.5% (38 calls)
-39.4%
stock -39% · XLV -10%
matured Jul 17, 25
Chardan Capital
Jun 26, 24
▲ Buy · 🎯$60
Price at call : $26.26 — upside +128%
Today : $58.13 — upside +3%
Expected +128% · Actual -39% · Reason (≥ +15%) : ✗ No
🎯 on ARWR : 42% (19 calls matureds) · 📊 on Health : 60.5% · +52.5% (38 calls)
-38.8%
stock -39% · XLV -8%
matured Jun 26, 25
▲ Overweight
Actual -39% · Reason (≥ +15%) : ✗ No
🎯 on ARWR : 63% (8 calls matureds) · 📊 on Health : 56.4% · +17.2% (117 calls)
-39.2%
stock -39% · XLV -10%
matured Jun 20, 25
▲ Buy · 🎯$60
Price at call : $25.29 — upside +137%
Today : $58.13 — upside +3%
Expected +137% · Actual -34% · Reason (≥ +15%) : ✗ No
🎯 on ARWR : 42% (19 calls matureds) · 📊 on Health : 60.5% · +52.5% (38 calls)
-33.8%
stock -34% · XLV -8%
matured Jun 3, 25
Chardan Capital
May 10, 24
▲ Buy · 🎯$60
Price at call : $22.06 — upside +172%
Today : $58.13 — upside +3%
Expected +172% · Actual -37% · Reason (≥ +15%) : ✗ No
🎯 on ARWR : 42% (19 calls matureds) · 📊 on Health : 60.5% · +52.5% (38 calls)
-36.7%
stock -37% · XLV -5%
matured May 10, 25
▲ Buy · 🎯$60
Price at call : $29.01 — upside +107%
Today : $58.13 — upside +3%
Expected +107% · Actual -11% · Reason (≥ +15%) : ✗ No
🎯 on ARWR : 42% (19 calls matureds) · 📊 on Health : 60.5% · +52.5% (38 calls)
-10.9%
stock -11% · XLV +11%
matured Aug 7, 24
▲ Overweight · 🎯$47
Price at call : $29.01 — upside +62%
Today : $58.13 — upside -19%
Expected +62% · Actual -11% · Reason (≥ +15%) : ✗ No
🎯 on ARWR : 63% (8 calls matureds) · 📊 on Health : 56.4% · +17.2% (117 calls)
-10.9%
stock -11% · XLV +11%
matured Aug 7, 24
▲ Buy · 🎯$55
Price at call : $36.08 — upside +52%
Today : $58.13 — upside -5%
Expected +52% · Actual -20% · Reason (≥ +15%) : ✗ No
🎯 on ARWR : 50% (10 calls matureds) · 📊 on Health : 52% · +22.0% (25 calls)
-20.3%
stock -20% · XLV +9%
matured Jul 19, 24
▲ Buy · 🎯$60
Price at call : $36.05 — upside +66%
Today : $58.13 — upside +3%
Expected +66% · Actual -32% · Reason (≥ +15%) : ✗ No
🎯 on ARWR : 42% (19 calls matureds) · 📊 on Health : 60.5% · +52.5% (38 calls)
-31.7%
stock -32% · XLV +11%
matured Jun 1, 24
Chardan Capital
May 24, 23
▲ Buy · 🎯$60
Price at call : $35.57 — upside +69%
Today : $58.13 — upside +3%
Expected +69% · Actual -31% · Reason (≥ +15%) : ✗ No
🎯 on ARWR : 42% (19 calls matureds) · 📊 on Health : 60.5% · +52.5% (38 calls)
-30.6%
stock -31% · XLV +12%
matured May 23, 24
Chardan Capital
Feb 10, 23
▲ Buy · 🎯$60
Price at call : $33.12 — upside +81%
Today : $58.13 — upside +3%
Expected +81% · Actual -3% · Reason (≥ +15%) : ✗ No
🎯 on ARWR : 42% (19 calls matureds) · 📊 on Health : 60.5% · +52.5% (38 calls)
-2.6%
stock -3% · XLV +9%
matured Feb 10, 24
▲ Buy · 🎯$55
Price at call : $33.16 — upside +66%
Today : $58.13 — upside -5%
Expected +66% · Actual -2% · Reason (≥ +15%) : ✗ No
🎯 on ARWR : 50% (10 calls matureds) · 📊 on Health : 52% · +22.0% (25 calls)
-1.8%
stock -2% · XLV +10%
matured Feb 8, 24
▲ Buy · 🎯$59
Price at call : $32.02 — upside +84%
Today : $58.13 — upside +1%
Expected +84% · Actual -28% · Reason (≥ +15%) : ✗ No
🎯 on ARWR : 50% (10 calls matureds) · 📊 on Health : 52% · +22.0% (25 calls)
-27.6%
stock -28% · XLV -5%
matured Nov 30, 23
Chardan Capital
May 11, 22
▲ Buy · 🎯$80
Price at call : $30.31 — upside +164%
Today : $58.13 — upside +38%
Expected +164% · Actual +30% · Reason (≥ +15%) : ✓ Yes
🎯 on ARWR : 42% (19 calls matureds) · 📊 on Health : 60.5% · +52.5% (38 calls)
+29.7%
stock +30% · XLV +4%
matured May 11, 23
▲ Buy · 🎯$94
Price at call : $62.78 — upside +50%
Today : $58.13 — upside +62%
Expected +50% · Actual -25% · Reason (≥ +15%) : ✗ No
🎯 on ARWR : 42% (19 calls matureds) · 📊 on Health : 60.5% · +52.5% (38 calls)
-25.1%
stock -25% · XLV -1%
matured Aug 6, 22
▲ Buy · 🎯$106
Price at call : $89.8 — upside +18%
Today : $58.13 — upside +82%
Expected +18% · Actual -39% · Reason (≥ +15%) : ✗ No
🎯 on ARWR : 50% (10 calls matureds) · 📊 on Health : 52% · +22.0% (25 calls)
-39.1%
stock -39% · XLV +16%
matured Feb 8, 22
▲ Buy · 🎯$97
Price at call : $90.47 — upside +7%
Today : $58.13 — upside +67%
Expected +7% · Actual -42% · Reason (≥ +15%) : ✗ No
🎯 on ARWR : 42% (19 calls matureds) · 📊 on Health : 60.5% · +52.5% (38 calls)
-42.4%
stock -42% · XLV +14%
matured Feb 5, 22
▲ Overweight · 🎯$58
Price at call : $34.14 — upside +70%
Today : $58.13 — upside -0%
Expected +70% · Actual +94% · Reason (≥ +15%) : ✓ Yes
🎯 on ARWR : 63% (8 calls matureds) · 📊 on Health : 56.4% · +17.2% (117 calls)
+93.6%
stock +94% · XLV +25%
matured May 8, 21
▲ Overweight · 🎯$60
Price at call : $35.33 — upside +70%
Today : $58.13 — upside +3%
Expected +70% · Actual +92% · Reason (≥ +15%) : ✓ Yes
🎯 on ARWR : 63% (8 calls matureds) · 📊 on Health : 56.4% · +17.2% (117 calls)
+92.4%
stock +92% · XLV +25%
matured Apr 15, 21
▲ Buy · 🎯$57
Price at call : $26.32 — upside +117%
Today : $58.13 — upside -2%
Expected +117% · Actual +173% · Reason (≥ +15%) : ✓ Yes
🎯 on ARWR : 50% (10 calls matureds) · 📊 on Health : 52% · +22.0% (25 calls)
+173.0%
stock +173% · XLV +27%
matured Mar 13, 21
▲ Buy · 🎯$59
Price at call : $48.51 — upside +22%
Today : $58.13 — upside +1%
Expected +22% · Actual +43% · Reason (≥ +15%) : ✓ Yes
🎯 on ARWR : 50% (10 calls matureds) · 📊 on Health : 52% · +22.0% (25 calls)
+42.7%
stock +43% · XLV +16%
matured Nov 12, 20
Chardan Capital
Oct 22, 19
▲ Buy · 🎯$45
Price at call : $38.97 — upside +15%
Today : $58.13 — upside -23%
Expected +15% · Actual +46% · Reason (≥ +15%) : ✓ Yes
🎯 on ARWR : 42% (19 calls matureds) · 📊 on Health : 60.5% · +52.5% (38 calls)
+45.5%
stock +46% · XLV +15%
matured Oct 21, 20
▲ Buy · 🎯$46
Price at call : $33.72 — upside +36%
Today : $58.13 — upside -21%
Expected +36% · Actual +32% · Reason (≥ +15%) : ✓ Yes
🎯 on ARWR : 50% (10 calls matureds) · 📊 on Health : 52% · +22.0% (25 calls)
+32.1%
stock +32% · XLV +17%
matured Aug 18, 20
▲ Overweight · 🎯$165
Price at call : $13.96 — upside +1082%
Today : $58.13 — upside +184%
Expected +1082% · Actual +372% · Reason (≥ +15%) : ✓ Yes
🎯 on ARWR : 63% (8 calls matureds) · 📊 on Health : 56.4% · +17.2% (117 calls)
+371.7%
stock +372% · XLV +17%
matured Dec 17, 19
▲ Buy · 🎯$24.5
Price at call : $19.74 — upside +24%
Today : $58.13 — upside -58%
Expected +24% · Actual +45% · Reason (≥ +15%) : ✓ Yes
🎯 on ARWR : 42% (19 calls matureds) · 📊 on Health : 60.5% · +52.5% (38 calls)
+45.4%
stock +45% · XLV -2%
matured Sep 6, 19
▲ Buy
Actual +63% · Reason (≥ +15%) : ✓ Yes
🎯 on ARWR : 50% (10 calls matureds) · 📊 on Health : 52% · +22.0% (25 calls)
+62.5%
stock +63% · XLV -1%
matured Sep 6, 19
▲ Overweight
Actual +116% · Reason (≥ +15%) : ✓ Yes
🎯 on ARWR : 63% (8 calls matureds) · 📊 on Health : 56.4% · +17.2% (117 calls)
+116.1%
stock +116% · XLV +10%
matured May 9, 19
Chardan Capital
Nov 30, 16
■ Neutral neutral · not a buy
🎯 on ARWR : 42% (19 calls matureds) · 📊 on Health : 60.5% · +52.5% (38 calls)
in progress (365j)
matures : Nov 30, 17
▲ Buy
Actual -70% · Reason (≥ +15%) : ✗ No
🎯 on ARWR : 63% (8 calls matureds) · 📊 on Health : 56.4% · +17.2% (117 calls)
-70.0%
stock -70% · XLV +5%
matured Aug 18, 17
Chardan Capital
May 19, 16
▲ Buy · 🎯$12
Price at call : $5.01 — upside +140%
Today : $58.13 — upside -79%
Expected +140% · Actual -67% · Reason (≥ +15%) : ✗ No
🎯 on ARWR : 42% (19 calls matureds) · 📊 on Health : 60.5% · +52.5% (38 calls)
-67.3%
stock -67% · XLV +9%
matured May 19, 17

Frequently asked questions

Should I buy Arrowhead Pharmaceuticals stock?

This isn't buy advice. For Arrowhead Pharmaceuticals, the analyst consensus is "Buy", with an average price target of $108 (+86% vs the current price). What matters is their past reliability on this stock: the most reliable one is right 75% of the time (4 calls tracked on Arrowhead Pharmaceuticals). We show the numbers — you decide.

Is it too late to buy Arrowhead Pharmaceuticals? How high can it go?

The most bullish analyst target on Arrowhead Pharmaceuticals is $126 (+117% above today's price); the average is $108. That's the upside they see. Check how reliable those analysts have actually been on Arrowhead Pharmaceuticals on our site before trusting it.

Is Arrowhead Pharmaceuticals still a good buy?

The most useful "opinion" isn't an opinion — it's a track record: 10 analysts have a real record on Arrowhead Pharmaceuticals, the best hitting 75% over 4 calls. Current consensus: "Buy". Make your call on data, not noise.

Should you invest in Arrowhead Pharmaceuticals? The case for and against

The arguments for and against, one by one, from the numbers: why invest in ARWR (and why hesitate).

What has Arrowhead Pharmaceuticals's past performance been?

Historical returns and a "how much if I had invested" calculator: ARWR performance & returns.

What is the best month to buy ARWR?

The 12 months ranked by the stock's past returns: best & worst month to buy ARWR.

Other Health stocks

Go further

JPI AI Analyst AI assistant · JPI Invest
Answers based on the tool’s data · not financial advice · full version (free)